In model II, MVD and p53 status were analyzed together with: (1) cancer immunophenotype, (2) tumor subgroups distinguished according to TOPOIIα expression and HER2 status and (3) cancer subtypes according to TOPOIIα expression and grade (Table 3). The gene discussed is ERBB2; the disease is neoplasm.